DexFV First Round of 100 Node Subscription Officially Starts at 15:00 (UTC+8) Today
On March 19, 2026, DexFV, the capital infrastructure of the on-chain market, officially announces the launch of its first round of node subscription at 15:00 (UTC+8) today, March 19, 2026. The first batch is limited to 100 slots.
As the core clearing and governance nodes of the DexFV ecosystem, this subscription is considered a golden slot for participating in the construction of the next-generation "on-chain Nasdaq."
Key Points:
Node Subscription Details: Subscription price is 2,000 USDT. Successful subscription will grant a 2,000 USDT 360-day financial order, providing a principal-backed asset hedge, opening the "zero-cost" entrepreneurship model.
Triple Dividend Sovereignty: Node holders can lock in long-term instant dividends of 30% of the network's sell-off tax, 20% of the profit tax, and 30% of the withdrawal fees.
Identity and Quota Leap: Immediate promotion to D3 level upon purchase, unlocking 30% team commission rights, and receiving 1,000 USDT of DX5 platform token’s initial quota.
Extreme Scarcity: The DX5 platform token will undergo a strict burn mechanism, reducing its supply from 100 million tokens to 2.1 million tokens. Node partners will have priority in capturing the premium dividends brought by ecosystem deflation.
Project Background:
DexFV is a next-generation capital infrastructure network for the on-chain market, integrating trading, liquidity, and capital scheduling through its "Five-Dimensional Unified" architecture.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
